Abstract
Objective
Financial toxicity has emerged as an important outcome in oncology, particularly in head and neck cancer, due to therapeutic complexity and prolonged functional consequences. This study aimed to map and synthesize the available evidence on financial toxicity in patients with head and neck cancer.
Methods
A scoping review was conducted in accordance with the Joanna Briggs Institute guidelines. Searches were performed in PubMed, Scopus, Embase, and Web of Science. After screening 1,466 studies, 29 met the eligibility criteria. Data were extracted by four reviewers, organized into a thematic matrix, and complemented by a bibliometric analysis using VOSviewer software.
Results
The studies, published between 2012 and 2025, showed that financial toxicity is frequent and multidimensional, involving direct costs (transportation, medications, food, and dental care related to oncological treatment) and indirect costs (loss of income and work absence). Factors such as low income, low educational level, informal employment, lack of insurance, and greater distance from treatment centers were associated with a higher risk of financial toxicity. This condition was associated with poorer quality of life, emotional distress, depressive symptoms, anxiety, treatment interruption or delay, and difficulties in returning to work. The most commonly used instrument was FACIT-COST, followed by FIT and author-developed questionnaires. Bibliometric analysis showed a concentration of studies in high-income countries and highlighted conceptual axes centered on “financial toxicity,” “quality of life,” and “treatment costs”.
Conclusion
Financial toxicity represents a relevant and multidimensional outcome in the care of patients with head and neck cancer, with important psychosocial implications. Its impacts are significant along the therapeutic trajectory and on quality of life, making its systematic inclusion in clinical assessment essential. There is a need to strengthen support systems and health policies that integrate financial, social, and psychological support, aiming to reduce inequalities and promote equity in access to oncological care.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-026-16700-0.
Keywords: Financial Toxicity, Head and Neck Neoplasms, Costs and Cost Analysis, Quality of Life, Health Inequalities
Introduction
Head and neck cancer (HNC) comprises a heterogeneous group of tumors that affect essential anatomical structures and whose treatment often involves high-complexity therapies, such as surgery, radiotherapy, chemotherapy, and immunotherapy [1]. Functional impairments and the need for prolonged care contribute to the occurrence of direct and indirect costs throughout the disease course, including medical expenses, transportation, loss of income, and rehabilitative support [2, 3].
Patients with head and neck cancer (HNC) experience high levels of financial toxicity, defined as the material, psychological, and behavioral hardships resulting from cancer-related treatment costs [2]. National and international studies have shown that patients with HNC experience greater financial toxicity than those with other types of cancer, owing to the combination of multimodal treatment, prolonged work absence, and the need for ongoing follow-up care [1]. Longitudinal evidence suggests that, even after treatment completion, healthcare-related costs remain substantially higher than pre-diagnosis levels, contributing to the persistence of financial toxicity for several years [1].Recent studies have identified several factors associated with financial toxicity in HNC, including sociodemographic characteristics, health insurance status, tumor site, treatment modality, and the presence of functional sequelae [3–5]. For example, patients with nasopharyngeal cancer have been reported to experience high levels of financial toxicity, often accompanied by coping strategies and a perceived need for social support [3]. Even among insured cancer survivors, financial toxicity persists, suggesting that health insurance coverage alone is not always sufficient to mitigate this outcome [2]. Financial difficulties may coexist with poorer quality of life, psychological distress, reduced work capacity, and the adoption of cost-coping behaviors, such as reducing activities, selling assets, borrowing money, and using personal savings [2].
The presence or absence of support systems, including social support, multidisciplinary care, and institutional strategies, plays a fundamental role in how individuals experience and cope with financial difficulties related to cancer [2, 5]. However, the organization and availability of these resources remain heterogeneous across different contexts, particularly in low- and middle-income countries, contributing to the exacerbation of health inequalities [2, 5].
Although the literature on financial toxicity in oncology has been growing, evidence related to head and neck cancer remains heterogeneous regarding definitions, instruments used, and dimensions evaluated. A recent systematic review synthesized aspects related to direct and indirect costs, quality of life, and coping strategies associated with financial toxicity in patients with head and neck cancer [6]. However, considering the recent expansion of the literature, there is still a need for a more comprehensive synthesis encompassing different methodological designs, healthcare contexts, and the economic, social, clinical, and psychosocial dimensions of financial toxicity.
In this context, scoping reviews allow for a broader mapping of the available evidence, the identification of knowledge gaps, and a better understanding of the conceptual organization of the topic across different care settings. Furthermore, the present review incorporates more recent studies and complementary bibliometric analysis, expanding the understanding of financial toxicity in patients with head and neck cancer.
A recent systematic review synthesized the evidence on financial toxicity in patients with head and neck cancer, highlighting direct and indirect costs, impacts on quality of life, and coping strategies [6]. However, the present scoping review expands this field by incorporating more recent studies, including evidence published up to 2025, different methodological designs (such as qualitative studies, economic analyses, and instrument validation), as well as complementary bibliometric analysis. This approach allows for a broader understanding of the clinical, psychosocial, economic, and structural dimensions of financial toxicity.
Given this scenario, the aim of this scoping review was to map and synthesize the available evidence on financial toxicity in patients with head and neck cancer, addressing the following research question: What evidence is available regarding financial toxicity in patients with head and neck cancer?
Methods
This scoping review was conducted following the methodological guidance of the Joanna Briggs Institute (JBI) for scoping reviews and reported in accordance with the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses – Scoping Review extension) checklist. The formulation of the research question and eligibility criteria was based on the Problem, Concept, and Context (PCC) framework, as recommended for this type of study.
The review protocol was developed a priori, including the definition of objectives, the design of the search strategy, the inclusion and exclusion criteria, and the procedures for study selection, data extraction, and data synthesis. Although the protocol was not registered in an open-access platform, all methodological steps were conducted in accordance with JBI and PRISMA-ScR recommendations.
Participants and context
Studies were eligible if they included individuals with head and neck cancer, encompassing, as defined in the original studies, tumors of the lip, oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, salivary glands, and other sites commonly grouped as head and neck cancer (ICD-10: C00–C14). No restrictions were applied regarding sex, disease stage, or treatment modality.
Regarding context, studies conducted in any country or healthcare system were considered, including public, private, or mixed settings, as well as outpatient and hospital services, and different phases of the care trajectory (diagnosis, active treatment, follow-up, and survivorship). Studies involving other types of cancer without specific analysis of patients with head and neck cancer were not included.
Concept
The conceptual criteria adopted in this review included studies addressing financial toxicity related to head and neck cancer in any of its dimensions, as evaluated by the authors of the original studies. Studies reporting individual-level financial measures were included, such as out-of-pocket expenses, loss of income, debt, work absence, financial coping strategies, perceived economic hardship, and other indicators related to the costs of diagnosis, treatment, or clinical follow-up.
Studies that used specific financial toxicity instruments or financial items incorporated into quality-of-life questionnaires to assess economic difficulties resulting from cancer and its treatment were also considered eligible.
In addition to quantitative studies, qualitative studies exploring financial experiences reported by patients with head and neck cancer or their caregivers were included, provided they presented data allowing the identification of economic difficulties of any nature. Studies evaluating population-level costs, aggregated health system analyses, or macroeconomic estimates without individual financial data were not considered eligible.
Studies involving exclusively pediatric populations or those that did not specify participants’ age range were also excluded, as were studies addressing other cancer types without presenting specific data for head and neck cancer, including thyroid cancer studies, since thyroid neoplasms present distinct clinical, therapeutic, and epidemiological characteristics. Likewise, studies that did not investigate financial toxicity or cancer-related economic impacts were excluded, in addition to narrative reviews, editorials, letters to the editor, protocols, publications without empirical data, and articles without full-text access.
Search strategy
The search strategy was initially developed for the MEDLINE database, accessed via PubMed, using descriptors from the Medical Subject Headings (MeSH) and free-text terms related to head and neck cancer and financial toxicity. This initial strategy was developed by the research group and subsequently adapted for the other databases consulted (Scopus, Embase, and Web of Science), taking into account the indexing specificities and syntax requirements of each platform. The complete search strategy is detailed in Supplementary Material 1.
For the development of the search strategy, terms related to head and neck neoplasms and financial toxicity were combined. The terms were connected using Boolean operators (AND/OR), with adjustments made according to the rules of each database.
No restrictions were applied regarding language, year of publication, or study design. Searches were conducted up to May 24, 2025.
Study selection
In the study selection process, the first step consisted of searching and importing records retrieved from the databases into the Rayyan reference management tool, where duplicate removal and initial screening of titles, abstracts, and keywords were performed. Potentially eligible studies were then subjected to full-text review, conducted by two independent and blinded reviewers, according to the eligibility criteria previously defined in the review protocol. In cases of disagreement between reviewers, a third reviewer was consulted to reach a final decision.
Studies that did not meet the inclusion criteria after full-text assessment were excluded, and the reasons for exclusion were recorded in detail. The flow diagram illustrating the process of identification, screening, eligibility, and inclusion of studies is presented according to the PRISMA extension for scoping reviews (Fig. 1).
Fig. 1.

Study selection flow diagram
Data extraction
Data extraction was performed by four reviewers divided into two groups, using a standardized and previously tested data extraction form. For each included study, information was collected regarding article identification (author, year of publication, and country), study design, characteristics of the study population, sample size, instruments used to measure financial toxicity, operational definitions adopted by the authors, and clinical aspects related to head and neck cancer.
In addition to these variables, the main outcomes assessed in each study were extracted, including objective and subjective indicators of financial toxicity, such as out-of-pocket expenses, loss of income, debt, financial coping strategies, measures of perceived financial burden, cost-related psychological distress, impacts on quality of life, and other associated economic, social, and clinical outcomes. The key findings of each study were also recorded, as presented in the data extraction spreadsheet.
Discrepancies between reviewers were resolved by consensus or, when necessary, with the involvement of a third reviewer. The consolidated data were organized into an electronic spreadsheet to facilitate descriptive synthesis and categorization of the results, following the approach recommended for scoping reviews.
Data analysis and presentation
The included studies were categorized according to their characteristics, the instruments used, and the outcomes assessed, integrating findings from quantitative, qualitative, and economic approaches. Data were organized based on the extraction spreadsheet and synthesized into tables containing general information about the studies.To support data visualization, VOSviewer software was used to construct the figures presented in the results, allowing graphical representation of themes and the conceptual organization of the findings.
Results
The database search yielded 1,466 records initially identified. After the removal of 791 duplicates, 675 studies were screened based on titles and abstracts. Of these, 53 articles were considered potentially relevant and assessed through full-text review. At the end of the selection process, 29 studies met the eligibility criteria and were included in the review synthesis, while the remaining studies were excluded for not assessing financial toxicity, not providing specific data on head and neck cancer, or not investigating economic or psychosocial outcomes related to the topic (Fig. 1). Acesso aberto.
The included studies are presented in Table 1. A predominance of studies conducted in North America was observed, followed by studies carried out in Asia and Europe. Regarding methodological design, cross-sectional studies predominated, followed by prospective, retrospective, qualitative, and instrument validation studies. The most commonly used instruments for assessing financial toxicity were the Comprehensive Score for Financial Toxicity (COST) and the Financial Index of Toxicity (FIT), in addition to author-developed questionnaires and quality-of-life instruments with financial domains.
Table 1.
Characteristics of studies included in the scoping review (n = 29)
| Author (year) | Country | Study design | Instrument | Main finding |
|---|---|---|---|---|
| Aguiar-Ibáñez et al. (2025) [7] | UNITED STATES | Cross-sectional study (survey) | WPAI:SHP and WPAI:CG (caregiver version) | Recurrence worsens finances, employment, productivity, and service use |
| Noel et al. (2023) [8] | CANADA | Cohort study | Financial Index of Toxicity (FIT) + HUI3 | Lower household income at diagnosis was associated with greater financial toxicity |
| Baddour et al. (2021) [9] | UNITED STATES | Cross-sectional study + claims analysis + survey | COST and FDQ | Lower family income and lack of health insurance were associated with greater financial toxicity |
| Balfe et al. (2016) [10] | IRELAND | Qualitative study | Semi-structured interviews | Head and neck cancer generates lasting financial and social impacts on survivors |
| Beeler et al. (2020) [11] | UNITED STATES | Prospective study | COST | Financial toxicity was associated with adverse clinical outcomes and non-adherence |
| Ben Dor et al. (2024) [12] | UNITED STATES | Cross-sectional study | Author-developed questionnaire | Financial toxicity was frequent, mainly affecting vulnerable groups |
| Chauhan et al. (2019) [13] | INDIA | Observational mixed-method study | Author-developed questionnaire | High treatment cost led many patients to debt and asset sales |
| Dar et al. (2023) [14] | INDIA | Cross-sectional study | COST and FACT-G | Need for interventions to reduce financial toxicity among cancer survivors |
| De Souza et al. (2017) [15] | UNITED STATES | Prospective longitudinal observational study | OOP costs; cost-coping; PSI; indirect cost/productivity | Greater toxicity was linked to higher economic burden and poorer adherence |
| Diao et al. (2023) [16] | UNITED STATES | Cross-sectional study | 9-item adapted financial toxicity questionnaire | Patients reported material sacrifice and financial concern |
| Egestad and Nieder (2015) [17] | NORWAY | Prospective longitudinal study | EORTC QLQ-C30 + EORTC QLQ-H&N35 | Financial difficulties remained stable during radiotherapy |
| Fan et al. (2025) [18] | CHINA | Cross-sectional study | Not applicable | High hospitalization costs and long length of stay were observed |
| Farrugia et al. (2021) [19] | UNITED STATES | Retrospective study | EORTC QLQ-C30 | Patients without financial counseling reported increased financial difficulty |
| Goswami et al. (2023) [20] | INDIA | Cross-sectional study | Author-developed questionnaire | Families adopted multiple financial coping strategies |
| Hueniken et al. (2020) [21] | CANADA | Instrument development and validation study | FIT | FIT showed good validity and reliability |
| Sun et al. (2024) [22] | CHINA | Cross-sectional study | COST-PROM | Greater financial toxicity was associated with higher suicide risk |
| Joshi et al. (2021) [5] | INDIA | Qualitative analysis | Semi-structured interviews | Four central themes were identified regarding financial burden |
| Khan et al. (2022) [23] | CANADA | Prospective observational study | OOPC questionnaire | Patients had significant direct costs and income loss |
| Lenze et al. (2022) [24] | UNITED STATES | Retrospective and cross-sectional study | PSQ-18, FACT-GP and PROMIS | Financial burden was associated with poorer quality of life |
| Lu et al. (2019) [25] | IRELAND | Cross-sectional study | FACT-G and FACT-HN | Financial difficulties were associated with worse quality of life |
| Luo et al. (2025) [3] | CHINA | Cross-sectional study | COST-PROM, MCMQ and PSSS | Financial toxicity incidence was 65.8% |
| Ma et al. (2021) [4] | UNITED STATES | Retrospective cohort study | EORTC QLQ-C30 | Higher financial toxicity was associated with worse survival |
| Mady et al. (2019) [2] | UNITED STATES | Cross-sectional study | COST, FDQ and UW-QOL v4 | Moderate to severe financial toxicity was frequent |
| Massa et al. (2022) [1] | UNITED STATES | Retrospective review and economic cohort evaluation | IBM MarketScan database | Higher risk of excessive costs in specific subgroups |
| Rast et al. (2024) [26] | GERMANY | Prospective study | Direct costs, income and income loss | Significant financial burden involving direct expenses and income loss |
| Rogers et al. (2012) [27] | ENGLAND | Cross-sectional study | Author-developed questionnaire | Financial impacts included transport, household costs, and income loss |
| Smith et al. (2023) [28] | AUSTRALIA | Cross-sectional study | COST and additional questionnaire | Higher financial toxicity was associated with worse quality of life |
| Smussi et al. (2025) [29] | ITALY | Cross-sectional study | FITALY | FITALY was validated as a multidimensional instrument |
| Thaduri et al. (2022) [30] | INDIA | Cross-sectional study | COST-Functional Assessment of Chronic Illness Therapy | Greater financial toxicity was associated with unemployment and worse mental health |
The populations investigated included patients undergoing active treatment, long-term survivors, and individuals submitted to different therapeutic modalities, including surgery, chemotherapy, radiotherapy, and multimodal approaches. Specific groups were also represented, such as residents of rural areas, informal workers, and individuals without health insurance coverage [2–4, 7, 9–11, 13–15, 18–20, 24–30]. The review also comprised studies describing the development and validation of financial toxicity assessment instruments [21, 29].
The thematic synthesis of the studies revealed that financial toxicity in patients with head and neck cancer is frequent and has a significant impact on daily life. Studies conducted in high-income countries identified high costs related to transportation, accommodation, nutritional supplements, dental consultations, and treatment-related payments [7, 28]. In rural or remote regions, these costs were even more pronounced, as demonstrated by Fan et al. [18], who identified additional expenses associated with the distance from the treatment center and the need for prolonged travel. In low- and middle-income countries, the economic burden was further aggravated by the lack of health insurance, resulting in indebtedness, asset sales, and treatment interruption [13, 20].
In addition to the direct financial impacts, several studies highlighted relevant psychosocial consequences. Higher levels of financial toxicity were associated with poorer quality of life, greater emotional distress, and increased symptoms of depression, anxiety, and stress, particularly among long-term survivors [24, 25, 30]. Socioeconomic vulnerability, characterized by low income, low educational attainment, informal employment, and lack of social support, was associated with higher levels of financial toxicity [2–4]. Other studies emphasized difficulties in returning to work, family dependence, and the forced reorganization of living standards as direct consequences of prolonged financial burden [5, 26].
Financial toxicity was also associated with clinical and functional outcomes, with patients experiencing greater financial burden presenting poorer health-related quality-of-life indicators and higher rates of treatment-related complications [28]. Qualitative studies further reinforced that fear of impoverishment, family guilt, loss of autonomy, and a sense of economic injustice permeate the illness experience and influence therapeutic decisions [4, 5, 10, 19].
In addition to the referenced findings, a visual thematic analysis was conducted using VOSviewer software to identify structural patterns within the included literature. The resulting figures graphically synthesize the findings and demonstrate how financial toxicity emerges from the interaction of individual, familial, structural, and social factors (Figs. 2, 3, and 4).
Fig. 2.

Density map of keywords related to financial toxicity in head and neck cancer
Fig. 3.

Temporal co-occurrence map of keywords related to financial toxicity in head and neck cancer
Fig. 4.

Co-citation network among authors
The density map visually highlights the most frequent terms in the literature. Areas shown in yellow represent a higher concentration of occurrences, revealing three central conceptual clusters: “financial toxicity”, “head and neck cancer,” and “quality of life”. These terms account for most of the scientific contributions on the topic, suggesting that the current focus of the literature is on understanding the economic impact of treatment and its psychosocial repercussions (Fig. 2).
The temporal map illustrates the evolution of research themes over time. Earlier terms (shown in blue) were centered on broader concepts, such as oral cancer and cancer survivors. More recent terms (shown in green and yellow), including out-of-pocket expenses, health services, and treatment costs, indicate the growing expansion of research toward the economic and structural dimensions of financial toxicity. This trend reflects the progressive development of the field toward the investigation of barriers to healthcare access and health inequalities. This evolution may reflect both increasing awareness of financial toxicity and its impact on patients' experiences and health outcomes, as well as growing interest in understanding how different healthcare financing models may influence patients' experiences. Furthermore, this shift parallels the progressive incorporation of health equity and financial protection as central components of both oncology research and health policy (Fig. 3).
The co-citation network reveals the structure of the included literature, highlighting three main clusters that organize authors according to their thematic contributions. The green cluster groups researchers primarily focused on quality of life, psychosocial outcomes, and patient experience, such as Mady, De Souza, Hueniken, and Rogers. The red cluster comprises authors from more recent studies, focusing on measurement instruments, direct costs, and economic burden, including Beeler, Ma, and Diao. The blue cluster includes authors with lower connection density, whose contributions appear more sporadic or methodological within the field. The lines connecting the nodes represent the strength of co-citation relationships, with thicker connections indicating a higher frequency of joint citation in the references of the analyzed studies (Fig. 4).
Discussion
The findings demonstrate that financial toxicity is a frequent and substantial outcome among patients with head and neck cancer, affecting multiple dimensions of their lives. Financial difficulties related to diagnosis, treatment, and follow-up care arise early in the disease trajectory and often persist for extended periods, encompassing direct costs, income loss, lifestyle changes, emotional distress, and barriers to continuity of care.
The included studies indicate that financial toxicity in head and neck cancer is a multifactorial phenomenon influenced by the combination of treatment complexity, prolonged work absence, and functional limitations resulting from cancer treatment [1, 2]. Direct expenses related to transportation, medications, nutritional supplements, dental care, and accommodation were frequently reported, particularly among individuals living far from treatment centers or requiring long-distance travel [7, 12, 23, 28]. In low- and middle-income countries, these costs were further exacerbated by the absence of health insurance, resulting in debt, asset liquidation, and substantial impacts on household income [13, 20, 26].
These findings suggest that the magnitude of financial toxicity is influenced by the organization of healthcare systems and the availability of social protection mechanisms. Although universal healthcare systems may reduce part of the direct costs associated with cancer treatment, patients often remain exposed to unreimbursed expenses, such as transportation, food, accommodation, and dental care, as well as income loss resulting from work absence [23, 28]. Conversely, in settings with limited healthcare coverage or no health insurance, simultaneous exposure to high direct and indirect costs tends to intensify debt, asset liquidation, and other financial coping strategies [13, 15, 20]. These findings reinforce that financial toxicity depends not only on the clinical characteristics of treatment but also on structural factors, including healthcare financing models, social protection mechanisms, and labor market conditions, which differentially shape the contribution of direct and indirect costs to patients' experiences of financial toxicity.
Beyond objective financial consequences, financial toxicity was consistently associated with psychosocial outcomes, including increased emotional distress, anxiety, depressive symptoms, and reduced quality of life [24, 25, 30]. Recent studies have also demonstrated associations between financial toxicity and more severe outcomes, including poorer survival and an increased risk of suicide among patients with head and neck cancer [8, 22]. Across several studies, individuals experiencing greater financial burden reported lower levels of well-being, poorer functional recovery, and a higher likelihood of delaying or interrupting treatment [11, 16, 28]. These findings suggest that financial toxicity is an important mediator throughout the treatment trajectory, influencing both clinical outcomes and subjective aspects of the illness experience.
Heterogeneity in the assessment of financial toxicity emerged as a critical issue across the included studies. Although most studies used validated instruments, such as the Comprehensive Score for Financial Toxicity (COST), which is widely employed to assess the economic impact of cancer, and the Financial Index of Toxicity (FIT), which was used less frequently [11, 21, 29], many studies also relied on author-developed questionnaires, qualitative interviews, and isolated indicators of financial burden. Additional studies reinforce the importance of standardizing and improving the comparability of instruments used to assess financial toxicity [16, 26]. The lack of standardization limits the systematic monitoring of this outcome across different healthcare settings and systems.
The qualitative studies included in this review provided additional insights into patients' lived experiences by exploring perceptions of vulnerability, financial insecurity, family reorganization, and fear of impoverishment [5, 10]. These accounts reveal that the financial impact extends beyond material hardship, encompassing feelings of guilt, loss of autonomy, and perceived economic injustice. In some settings, the need to offset treatment-related expenses led individuals to reduce essential expenditures, take out loans, sell personal assets, or forgo everyday activities, reinforcing the structural nature of this problem.
Another important finding was the influence of socioeconomic and structural factors on the severity of financial toxicity. Low income, low educational attainment, informal employment, lack of social support, and residence in rural or geographically remote areas consistently emerged as determinants of greater financial hardship [3, 4, 12, 28]. Healthcare systems with partial or limited coverage further exacerbated these disparities, whereas countries with universal healthcare systems experienced financial toxicity more frequently related to indirect costs and income loss than to direct medical expenses.
The synthesis of the included studies also showed that financial toxicity affects continuity of care and may compromise clinical outcomes. Prolonged financial hardship was associated with poorer health-related quality of life, increased complications, and greater difficulties in treatment adherence [16, 17, 24, 28]. Although few studies evaluated interventions, preliminary evidence suggests that strategies such as financial counseling may reduce perceived financial toxicity and improve patients' ability to cope with financial challenges [19].
From a clinical perspective, these findings reinforce the importance of early screening for financial toxicity as part of the comprehensive assessment of patients with cancer [11, 19]. Within nursing practice and multidisciplinary care, continuous follow-up plays a key role in identifying socioeconomic vulnerabilities and providing guidance on coping strategies [10, 19]. Regarding social support, the findings highlight the need to strengthen family, community, and institutional support networks capable of mitigating the financial impact of cancer treatment [5, 10, 15]. From a health policy perspective, expanding social protection mechanisms and reducing financial barriers to access and continuity of care are essential [13, 20, 26]. Finally, from a research perspective, there is a pressing need to strengthen investigations in low- and middle-income countries and generate evidence to support strategies for the prevention and management of financial toxicity [21, 26, 29].
Despite the advances identified, important gaps remain. The concentration of studies in high-income countries limits the global understanding of this phenomenon. The scarcity of longitudinal studies hinders the evaluation of the persistence of financial toxicity over time, and the lack of Brazilian studies represents a critical gap given the epidemiological relevance of head and neck cancer and the country's socioeconomic inequalities. In this context, longitudinal studies following the evolution of financial toxicity throughout the treatment trajectory, qualitative investigations exploring patients' coping strategies, and studies employing standardized, culturally adapted, and validated instruments to assess this outcome are needed. These priorities are particularly relevant for Brazil and other low- and middle-income countries, where socioeconomic inequalities and healthcare system characteristics may substantially influence patients' experiences of financial toxicity.
In summary, financial toxicity among patients with head and neck cancer represents a complex, multifactorial, and still insufficiently addressed challenge. The findings of this review indicate that the phenomenon occurs across diverse healthcare settings, affects the material, emotional, and social dimensions of patients' lives, and has important implications for treatment adherence and clinical outcomes. Advancing the understanding and management of financial toxicity will require greater conceptual standardization, expanded research in low- and middle-income countries, the development of supportive interventions, and the integration of financial toxicity into oncology care policies.
Conclusion
Financial toxicity in patients with head and neck cancer was associated with material, emotional, and clinical impacts. The included studies showed that direct and indirect expenses, loss of income, changes in living standards, and psychological distress compose a scenario of economic vulnerability, especially among individuals with lower income, less social support, and those living in rural areas.
Although addressing similar dimensions, the studies presented substantial conceptual and methodological heterogeneity, which limits the comparability of results and highlights the need for standardization in the assessment of financial toxicity. In addition, the predominance of studies conducted in high-income countries reveals important gaps in contexts of greater inequality, such as Brazil.
In light of these findings, financial toxicity should be recognized as a relevant and multidimensional outcome in oncology care, warranting its routine assessment and the implementation of strategies for early identification.
Expanding research in low- and middle-income countries, including longitudinal studies and investigations that consider the specific characteristics of different socioeconomic contexts, is essential to improve understanding of existing inequalities and to inform interventions that promote greater equity in the care of patients with head and neck cancer.
Supplementary Information
Acknowledgements
The authors would like to thank all researchers whose studies were included in this review.
Abbreviations
- HNC
Head and Neck Cancer
- COST
Comprehensive Score for Financial Toxicity
- FIT
Financial Index of Toxicity
- JBI
Joanna Briggs Institute
- PRISMA-ScR
Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews
Authors’ contributions
Danielle Karla Vieira e Silva contributed to the conception and design of the study, data collection, data analysis, and manuscript writing. Rênnis Oliveira da Silva contributed to data extraction, data analysis, and manuscript preparation. Sarah Verônica Andrade Silva contributed to data analysis, interpretation of results, and manuscript review. Maria Letícia Barbosa Raymundo contributed to data extraction, organization of results, and manuscript preparation. Débora Lana Alves Monteiro contributed to data extraction and figure preparation. Wenner Gláucio Lopes Lucena contributed to study supervision, critical revision of the manuscript, and final approval of the version to be published. Yuri Wanderley Cavalcanti contributed to study supervision, critical revision of the manuscript, and final approval of the version to be published.
Funding
The authors received no specific funding for this study.
Data availability
All data analyzed in this study are included in this published article and its supplementary information files.
Declarations
Ethics approval and consent to participate
Not applicable. This study is a scoping review based on previously published studies and does not involve human participants directly.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Massa ST, Chidambaram S, Luong P, Graboyes EM, Mazul AL. Total and out-of-pocket costs in head and neck cancer survivorship. JAMA Otolaryngol Head Neck Surg. 2022;148(12):1111–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mady LJ, Lyu L, Owoc MS, Peddada SD, Thomas TH, Sabik LM, et al. Understanding financial toxicity in head and neck cancer survivors. Oral Oncol. 2019;95:187–93. [DOI] [PubMed] [Google Scholar]
- 3.Luo Q, Chen X, Liu L, Peng J, Tang F. Financial toxicity-related factors in patients with nasopharyngeal carcinoma: a cross-sectional study. Support Care Cancer. 2025;33(3):201. [DOI] [PubMed] [Google Scholar]
- 4.Ma SJ, Iovoli AJ, Attwood K, Wooten KE, Arshad H, Gupta V, et al. Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy. Oral Oncol. 2021;115:105196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Joshi S, Joshi U, Bahl A, Arya D, Anand A, Arora R. Exploring the financial toxicities of patients with locally advanced head and neck malignancies: a thematic analysis. Indian J Palliat Care. 2021;27(1):118–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Rosi-Schumacher M, Patel S, Phan C, Goyal N. Understanding financial toxicity in patients with head and neck cancer: a systematic review. Clin Med Insights Oncol. 2023;17:1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Aguiar-Ibáñez R, McQuarrie K, Jayade S, Penton H, DiGiovanni L, Raina R, et al. Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: a US survey. Future Oncol. 2025;21(3):349–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Noel CW, Hueniken K, Forner D, Liu G, Eng L, Hosni A, et al. Association of household income at diagnosis with financial toxicity, health utility, and survival in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2023;149(1):63–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Baddour K, Fadel M, Zhao M, Corcoran M, Owoc MS, Thomas TH, et al. The cost of cure: financial toxicity in head and neck cancer survivors. Head Neck. 2021;43(10):3062–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Balfe M, Butow P, O’Sullivan E, Gooberman-Hill R, Timmons A, Sharp L. Financial impact of head and neck cancer caregiving: a qualitative study. Psychooncology. 2016;25(12):1441–7. [DOI] [PubMed] [Google Scholar]
- 11.Beeler WH, Bellile EL, Casper KA, Jaworski E, Burger NJ, Malloy KM, et al. Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncol. 2020;101:104521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ben Dor B, Villa A, Hayes C, Alpert E, Shepard DS, Sonis ST. Financial burden of dental care among patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2024;150(9):811–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Chauhan AS, Prinja S, Ghoshal S, Verma R. Economic burden of head and neck cancer treatment in North India. Asian Pac J Cancer Prev. 2019;20(2):403–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Dar MA, Chauhan R, Trivedi V, Kumar R, Dhingra S. Assessing the prevalence of financial toxicity, its predictors and association with health-related quality of life among radiation oncology patients in India: a cross-sectional patient-reported outcome study. Int J Radiat Oncol Biol Phys. 2023;116(1):157–65. [DOI] [PubMed] [Google Scholar]
- 15.De Souza JA, Kung S, O’Connor J, Yap BJ. Determinants of patient-centered financial stress in patients with locally advanced head and neck cancer. J Oncol Pract. 2017;13(4):e310–8. [DOI] [PubMed] [Google Scholar]
- 16.Diao K, Lei X, Smith GL, Jagsi R, Peterson SK, Sumer BD, et al. Patient-reported financial toxicity in oropharynx cancer survivors. Int J Radiat Oncol Biol Phys. 2023;116(1):142–53. [DOI] [PubMed] [Google Scholar]
- 17.Egestad H, Nieder C. Financial effects of head and neck cancer radiotherapy during initial treatment. Int J Circumpolar Health. 2015;74:26686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fan Y, Yang Q, Chen C, Hu X, Xu M, Weng Y, et al. Factors influencing length of stay and hospitalisation expenses for oral cancer patients: a cross-sectional study. BMJ Open. 2025;15(1):e087060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Farrugia M, Yu H, Ma SJ, Iovoli AJ, Erickson K, Wendel E, et al. Financial counseling is associated with reduced financial difficulty scores in head and neck cancer patients treated with radiation therapy. Cancers (Basel). 2021;13(11):2516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Goswami S, Gupta S, Gangane N, Vyas V, Royburman A. Financial impact of oral cancer treatment on households in rural India. Indian J Cancer. 2023;60(3):379–85. [DOI] [PubMed] [Google Scholar]
- 21.Hueniken K, Douglas CM, Jethwa AR, Mirshams M, Eng L, Hope A, et al. Measuring financial toxicity after treatment of head and neck cancer: development and validation of the financial index of toxicity questionnaire. Cancer. 2020;126(17):4042–50. [DOI] [PubMed] [Google Scholar]
- 22.Sun MC, Feng FM, Wang XY, Yang FF, Zhao MH, Meng J. Investigation and correlation analysis of financial toxicity and suicide risk in patients with head and neck cancer in China. 2024. Available from: https://www.researchsquare.com/article/rs-3934310/v1. Cited 2025 Dec 4
- 23.Khan MN, Hueniken K, Manojlovic-Kolarski M, Eng L, Mirshams M, Khan K, et al. Out-of-pocket costs associated with head and neck cancer treatment. Cancer Rep (Hoboken). 2022;5(7):e1528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lenze NR, Bensen JT, Farnan L, Sheth S, Zevallos JP, Yarbrough WG, et al. Association of self-reported financial burden with quality of life and oncologic outcomes in head and neck cancer. Head Neck. 2022;44(2):412–9. [DOI] [PubMed] [Google Scholar]
- 25.Lu L, O’Sullivan E, Sharp L. Cancer-related financial hardship among head and neck cancer survivors: risk factors and associations with health-related quality of life. Psychooncology. 2019;28(4):863–71. [DOI] [PubMed] [Google Scholar]
- 26.Rast J, Zebralla V, Dietz A, Wichmann G, Wiegand S. Cancer-associated financial burden in German head and neck cancer patients. Front Oncol. 2024;14:1329242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Rogers SN, Harvey-Woodworth CN, Hare J, Leong P, Lowe D. Patients’ perception of financial impact of head and neck cancer and its relationship with quality of life. Br J Oral Maxillofac Surg. 2012;50(5):410–6. [DOI] [PubMed] [Google Scholar]
- 28.Smith J, Yu J, Gordon LG, Chilkuri M. Financial toxicity and out-of-pocket costs for patients with head and neck cancer. Curr Oncol. 2023;30(5):4922–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Smussi D, Conti C, Lorini L, Mattavelli D, Levaggi R, Miniaci R, et al. Financial toxicity questionnaire (FIT): development and validation of the Italian version in head and neck cancer patients. BMC Cancer. 2025;25(1):283. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Thaduri A, Garg PK, Malhotra M, Singh MP, Poonia DR, Priya M, et al. Financial toxicity and mental well-being of oral cancer survivors in a developing country during the COVID-19 pandemic: a cross-sectional study. Psychooncology. 2023;32(1):58–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data analyzed in this study are included in this published article and its supplementary information files.
